The Effect of Artificial Liver Support System on Prognosis of HBV-Derived Hepatorenal Syndrome: A Retrospective Cohort Study
Table 3
Characteristics between SMT and ALSS after PSM.
Variates
SMT
ALSS
value
n
150
50
Age (year)
0.796
HBV-DNA (log copies/mL)
0.990
Male sex
124 (82.70)
42 (84.00)
1.000
Degree of HE
0.109
Without HE
81 (54.00)
23 (46.00)
I
24 (16.00)
6 (12.00)
II
7 (4.70)
7 (14.00)
III
9 (6.00)
6 (12.00)
IV
29 (19.30)
8 (16.00)
Ascitic (%)
0.007
Grade 1
30 (20.00)
12 (24.00)
Grade 2
37 (24.70)
23 (46.00)
Grade 3
52 (34.70)
7 (14.00)
Missing data
31 (20.70)
8 (16.00)
MAP (mmHg)
0.683
HR
0.399
INR
2.01 (1.68-2.82)
2.08 (1.74-2.63)
0.536
WBC (109/L)
7.15 (4.70-10.38)
6.55 (5.05-9.58)
0.241
Neutrophil (%)
0.563
Albumin (g/L)
0.777
Globulin (g/L)
0.654
ALT (U/L)
57.00 (25.50-127.00)
114.00 (54.75-253.50)
0.273
AST (U/L)
90.50 (49.75-205.00)
144.50 (92.50-282.00)
0.511
Hemoglobin (g/L)
<0.001
Cystatin C (mg/L)
2.14 (1.44-3.44)
1.24 (0.92-1.70)
0.007
Urea (mmol/L)
14.81 (6.75-23.82)
7.95 (4.26-14.50)
0.001
Creatinine (mg/dL)
1.80 (1.01-2.95)
0.93 (0.71-1.61)
<0.001
Serum bilirubin (mg/dL)
14.12 (3.95-25.28)
20.07 (10.64-28.13)
0.079
GGT (U/L)
50.00 (33.00-119.00)
61.50 (45.75-99.50)
0.501
Potassium (mmol/L)
0.480
Sodium (mmol/L)
0.074
MELDs
0.113
iMELD
0.034
CTP
0.259
CLIF-ACLFs
0.450
CLIF-SOFAs
0.527
COSSH-ACLFs
0.260
Liver failure
84 (56.00)
35 (70.00)
0.114
Coagulation failure
50 (33.30)
16 (32.00)
1.000
Cerebral failure
38 (25.30)
14 (28.00)
0.852
28-day mortality
96 (64.00)
24 (48.00)
0.067
ALT: alanine aminotransferase; CLIF-SOFA: Chronic Liver Failure-Sequential Organ Failure Assessment; COSSH-ACLF: Chinese Group on the Study of Severe Hepatitis B-Acute-on-Chronic Liver Failure; HBV: hepatitis B virus; INR: international normalized ratio; MAP: mean arterial pressure; MELD: Model for End-Stage Liver Disease.
